Protocol Ledger

NCT07140913 · Phase III · RECRUITING

A Study to Evaluate the Efficacy and Safety of Adjunctive KarXT for the Treatment of Mania, With or Without Mixed Features, in Participants With Bipolar-I Disorder Taking Lithium, Valproate, or Lamotrigine

Interventional Phase III clinical trial protocol NCT07140913 sponsored by Bristol Myers Squibb in Neurology, Psychiatry, and Pain, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2025-10-08 Enrollment: 424 participants (ESTIMATED) Federal Source: clinicaltrials.gov/study/NCT07140913
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)424 participants (ESTIMATED)
Disclosed U.S. Hospital Campuses vs Median (6 sites)3 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT07140913
Protocol FieldVerified Registry Value
NCT IdentifierNCT07140913
Consolidated Lead SponsorBristol Myers Squibb
Therapeutic Condition CohortNeurology, Psychiatry, and Pain
Clinical Trial PhasePhase III
Overall Recruitment StatusRECRUITING
Registered Enrollment424 participants (ESTIMATED)
Registered Start Date2025-10-08
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Canonical Hospital Campuses Listed on NCT07140913
Hospital Research SiteLocationSite Profile
ProScience Research GroupCulver City, CAOpen Hospital Dossier ->
Catalina Research Institute, LLCMontclair, CAOpen Hospital Dossier ->
NRC Research InstituteOrange, CAOpen Hospital Dossier ->

Related Filings Across Meru Platforms

Verified cross-ledger federal filings for Bristol Myers Squibb across sibling Meru public-data platforms.

Search related sites and sponsors in the Interactive Directory, explore Neurology, Psychiatry, and Pain Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI